Ardelyx (NASDAQ: ARDX) — Perfil da empresa, notícias e dados financeiros
Ardelyx is dedicated to developing medicines for kidney and cardiovascular diseases, addressing significant unmet medical needs.
Ardelyx
Ardelyx (NASDAQ:ARDX) specializes in discovering, developing, and commercializing innovative medicines to improve treatment for people with kidney and cardiovascular diseases. The company is focused on addressing unmet medical needs, particularly in the realms of cardiorenal diseases, a term that refers to heart conditions that are caused or worsened by kidney problems. Ardelyx’s commitment is towards projects that leverage its unique understanding of kidney function and the mechanisms behind these conditions. Its main objectives include advancing its lead drug candidates through clinical trials, securing regulatory approvals, and establishing strategic partnerships to ensure the broadest possible access to its therapies.
Resumo
Operações
Produtos e/ou serviços de Ardelyx
- Ibsrela: A prescription medicine used for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults.
- Xphozah: An FDA-approved treatment for control of serum phosphorus in adults with chronic kidney disease on dialysis.
- RDX013: A potassium secretagogue in development for the potential treatment of hyperkalemia, a condition characterized by elevated potassium levels.
- RDX020: An investigational drug aimed at treating metabolic acidosis, a condition where there is too much acid in the body fluids.
- Tenapanor: In clinical testing for its ability to reduce abdominal pain and improve bowel habits in patients with irritable bowel syndrome.
- Research and Development: Focused on discovering and developing innovative treatments for gastrointestinal and cardio-renal diseases.
equipe executiva do Ardelyx
- Michael G. RaabPresident, CEO & Director
- Sue HohenleitnerChief Financial Officer
- John BishopChief Technical & Quality Officer
- Joseph ReillySenior VP of Finance & Principal Accounting Officer
- Lisa M. CaperelliSenior Vice President of Investor Relations and Corporate Communications
- Felecia W. EttenbergChief Legal Officer
- James P. BradyChief Human Resources Officer
- Laura A. WilliamsChief Patient Officer Emeritus
- Mike KelliherChief Business Officer
- Rajani DinavahiChief Medical Officer
Principais indicadores financeiros
Resultados divulgados pela Ardelyx, em USD.
- Cap. de mercado
- 800,4 mi
- Receita (TTM)
- 450,9 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.2
- Dividend yield
- —
- Margem de lucro
- -12.3%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 407,3 mi | -41 mi | -61,6 mi | |
| 333,6 mi | -28 mi | -39,1 mi | |
| 124,5 mi | -63,3 mi | -66,1 mi | |
| 52,2 mi | -63,8 mi | -67,2 mi |